De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Cordlife Group Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor Cordlife Group te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Healthcare winstgroei	18.1%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Geen updates

Recent updates

Cordlife Group Limited (SGX:P8A) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough

May 06

Risks Still Elevated At These Prices As Cordlife Group Limited (SGX:P8A) Shares Dive 31%

Mar 22

Estimating The Fair Value Of Cordlife Group Limited (SGX:P8A)

Sep 07

Cordlife Group (SGX:P8A) Will Be Hoping To Turn Its Returns On Capital Around

Aug 02

Cordlife Group (SGX:P8A) Might Be Having Difficulty Using Its Capital Effectively

Apr 03

Cordlife Group (SGX:P8A) Is Looking To Continue Growing Its Returns On Capital

Oct 15

Cordlife Group's (SGX:P8A) Problems Go Beyond Weak Profit

Aug 22

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Cordlife Group onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

SGX:P8A - Toekomstschattingen van analisten en financiële gegevens uit het verleden (SGD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2024	37	-11	-5	-2	N/A
3/31/2024	46	-4	1	4	N/A
12/31/2023	56	4	7	10	N/A
9/30/2023	56	4	9	12	N/A
6/30/2023	57	5	10	13	N/A
3/31/2023	56	5	7	10	N/A
12/31/2022	55	5	5	8	N/A
9/30/2022	55	5	5	7	N/A
6/30/2022	56	6	5	6	N/A
3/31/2022	56	6	6	8	N/A
12/31/2021	57	6	8	10	N/A
9/30/2021	58	6	10	12	N/A
6/30/2021	60	6	12	14	N/A
3/31/2021	60	6	13	15	N/A
12/31/2020	59	7	15	16	N/A
9/30/2020	59	8	14	15	N/A
6/30/2020	58	7	12	14	N/A
3/31/2020	58	7	10	12	N/A
12/31/2019	62	6	10	12	N/A
9/30/2019	60	3	7	8	N/A
6/30/2019	59	2	4	5	N/A
3/31/2019	69	4	5	6	N/A
12/31/2018	60	2	5	7	N/A
6/30/2018	68	3	7	9	N/A
3/31/2018	67	3	N/A	8	N/A
12/31/2017	62	-1	N/A	5	N/A
9/30/2017	62	-1	N/A	4	N/A
6/30/2017	60	-3	N/A	4	N/A
3/31/2017	60	-6	N/A	0	N/A
12/31/2016	60	-7	N/A	0	N/A
9/30/2016	60	4	N/A	-1	N/A
6/30/2016	60	12	N/A	-4	N/A
3/31/2016	60	36	N/A	-3	N/A
12/31/2015	59	56	N/A	-4	N/A
9/30/2015	59	43	N/A	-5	N/A
6/30/2015	58	32	N/A	-3	N/A
3/31/2015	56	28	N/A	0	N/A
12/31/2014	53	11	N/A	1	N/A
9/30/2014	51	18	N/A	4	N/A
6/30/2014	49	31	N/A	4	N/A
3/31/2014	45	18	N/A	3	N/A
12/31/2013	40	18	N/A	4	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van P8A boven de spaarquote ( 2.2% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van P8A naar verwachting sneller zal groeien dan de markt SG

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van P8A naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van P8A naar verwachting sneller zal groeien dan de markt SG.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van P8A naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van P8A naar verwachting over 3 jaar hoog zal zijn

Cordlife Group Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Cordlife Group Limited Announces Cessation of Tan Huiying as Group Director, Quality and Operations, Effective 4 November 2024

Cordlife Group Limited Announces Re-Designation of Chen Xiaoling from Non-Independent Non-Executive Director to Group Executive Director

High number of new and inexperienced directors

Cordlife Group Limited Announces Changes to the Composition of Board and the Board Composition

Cordlife Group Limited Announces Retirement of Cheong Tuck Yan Titus Jim as Independent Director

Cordlife Group Limited Announces the Appointment of Dato' Dr. Teo Tong Kooi as Independent Non-Executive Director, Effective May 14, 2024

Cordlife Group Limited Announces Directors Removal

Cordlife Group Limited (SGX:P8A) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough

Cordlife Group Limited Announces Board Changes

Cordlife Group Limited Announces Board Resignations

New minor risk - Share price stability

Cordlife Group Limited has filed a Follow-on Equity Offering in the amount of SGD 8.191276 million.

Cordlife Group Limited has filed a Follow-on Equity Offering in the amount of SGD 8.191276 million.

Risks Still Elevated At These Prices As Cordlife Group Limited (SGX:P8A) Shares Dive 31%

New minor risk - Financial data availability

Full year 2023 earnings released: EPS: S$0.015 (vs S$0.019 in FY 2022)

Cordlife Group Limited Announces Changes in the Composition of the Board and Board Committees

New minor risk - Financial data availability

Cordlife Group Limited Announces the Cessation of Tan Poh Lan as Executive Director

Now 34% undervalued after recent price drop

Cordlife Group Limited Announces Resignation of Ms. Tan Poh Lan as a Group Chief Executive Officer, Effective 31 March 2024

Estimating The Fair Value Of Cordlife Group Limited (SGX:P8A)

New minor risk - Earnings quality

First half 2023 earnings released: EPS: S$0.009 (vs S$0.007 in 1H 2022)

Cordlife Group (SGX:P8A) Will Be Hoping To Turn Its Returns On Capital Around

New minor risk - Market cap size

Cordlife Group Limited Announces Change of Company Secretary

Cordlife Group Limited Announces Resignation of Kuan Yoke Kay as the Joint Company Secretary

Full year 2022 earnings released: EPS: S$0.019 (vs S$0.024 in FY 2021)

Cordlife Group (SGX:P8A) Might Be Having Difficulty Using Its Capital Effectively

Full year 2022 earnings released: EPS: S$0.019 (vs S$0.024 in FY 2021)

Now 20% undervalued after recent price drop

Cordlife Group Limited Appoints that Hnin Yi as Group Chief Financial Officer

Now 20% undervalued after recent price drop

Now 28% undervalued after recent price drop

High number of new directors

Cordlife Group Limited to Report Q1, 2023 Results on Nov 24, 2022

Cordlife Group (SGX:P8A) Is Looking To Continue Growing Its Returns On Capital

Cordlife Group Limited Announces Resignation of Choo Boon Yong as Group Chief Financial Officer

High number of new directors

Cordlife Group Limited Approves Final Tax Exempt (1-Tier) Dividend for the Financial Year Ended 31 December 2021

High number of new directors

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Cordlife Group Limited Proposes Final Tax Exempt Dividend for the Year Ended December 31, 2021, Payable on May 27, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Cordlife Group Limited Appoints Kuan Yoke Kay as the Joint Company Secretary

High number of new directors

Non-Independent Non-Executive Director Lin Wang has left the company

Cordlife Group's (SGX:P8A) Problems Go Beyond Weak Profit

Cordlife Group Limited Approves Final Dividend for the Financial Year Ended 31 December 2020, Payable on 28 May 2021

Cordlife Group Limited Announces the Launch of OptiQ

Global Cord Blood Corporation (NYSE:CO) cancelled the acquisition of Cordlife Group Limited (SGX:P8A) in a reverse merger transaction.

New 90-day high: S$0.40

Cordlife Group Limited Announces Resignation of Goh Jin Hian from the Position of Independent Director

First half earnings released

New 90-day high - S$0.40

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven